


PE 22-28

Cat. No.:	HY-P3581
CAS No.:	1801959-12-5
Molecular Formula:	C ₃₅ H ₅₅ N ₁₁ O ₉
Molecular Weight:	773.88
Sequence Shortening:	GVSWGLR
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PE 22-28 is a TREK-1 inhibitor with IC ₅₀ value of 0.12 nM. PE 22-28 also is a 7 amino-acid peptide that is used as a core sequence for preparing analogs by chemical modifications and also by substitution of amino-acids. PE 22-28 can be used for the research of depression ^[1] .								
IC₅₀ & Target	IC ₅₀ : 0.12 nM (TREK-1) ^[1]								
In Vitro	PE 22-28 displays good specificity and affinity for TREK-1 channel with IC ₅₀ value of 0.12 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	PE 22-28 (i.p.; 3.0μg/kg) shows antidepressant property ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Naïve male C57Bl/6J mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>3.0μg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal</td> </tr> <tr> <td>Result:</td> <td>Showed a significant reduction of the immobility time, reduced significantly the latency to eat the food pellet, induced neurogenesis and improved the action duration.</td> </tr> </table>	Animal Model:	Naïve male C57Bl/6J mice ^[1]	Dosage:	3.0μg/kg	Administration:	Intraperitoneal	Result:	Showed a significant reduction of the immobility time, reduced significantly the latency to eat the food pellet, induced neurogenesis and improved the action duration.
Animal Model:	Naïve male C57Bl/6J mice ^[1]								
Dosage:	3.0μg/kg								
Administration:	Intraperitoneal								
Result:	Showed a significant reduction of the immobility time, reduced significantly the latency to eat the food pellet, induced neurogenesis and improved the action duration.								

REFERENCES

[1]. Alaeddine Djillani, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017 Sep 12;8:643.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA